Submit Deal
All corporates
Similar corporates
Summary
Inhibrx is a clinical-stage biopharmaceutical company focused on developing biologic therapeutics in oncology and orphan diseases.
Deals Overview
Market Context
All Corporates
Back to top
All rights reserved. Copyright © 2025 Datasite
Senior Management
Mark P. Lappe
Founder and CEO
Deals (1)
Service Providers
Relationships
Portfolio
Team
Sort
Target: INHIBRX
Bidder: SANOFI SA
9 Service Providers
62 Dealmakers
£ 1.34 B
Value
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy